T L Timme
Overview
Explore the profile of T L Timme including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, Yang G, Timme T, Fujita T, Naruishi K, Frolov A, et al.
Cancer Gene Ther
. 2007 Jul;
14(10):819-27.
PMID: 17627292
To investigate the immunomodulatory effects of interleukin-12 (IL-12) for treatment of metastatic prostate cancer, we administered adult bone marrow cells (BMC) that were genetically modified by retroviral vector-mediated IL-12 gene...
2.
Fujita T, Timme T, Tabata K, Naruishi K, Kusaka N, Watanabe M, et al.
Gene Ther
. 2006 Oct;
14(3):227-36.
PMID: 17024109
We investigated the potential benefits of combining adenoviral vector mediated in situ interleukin-12 (AdmIL-12) gene therapy with radiation therapy (XRT) to enhance therapeutic efficacy. In a metastatic mouse prostate cancer...
3.
Naruishi K, Timme T, Kusaka N, Fujita T, Yang G, Goltsov A, et al.
Cancer Gene Ther
. 2006 Feb;
13(7):658-63.
PMID: 16485011
We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential...
4.
Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme T, et al.
Cancer Gene Ther
. 2005 Jul;
13(1):91-8.
PMID: 16052232
We developed a preclinical prostate cancer model to study the feasibility of adoptive immunotherapy for residual tumor following neo-adjuvant in situ adenoviral-vector-mediated interleukin 12 (AdIL-12) gene therapy. Splenocytes were obtained...
5.
Thompson T, Timme T, Li L, Goltsov A
Apoptosis
. 2003 Nov;
4(4):233-7.
PMID: 14634273
Metastasis represents the ultimate target in cancer therapy as this complex biological process is the direct cause of mortality for a variety of human malignancies. The current high level of...
6.
Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, et al.
Prostate Cancer Prostatic Dis
. 2003 Mar;
5(4):316-25.
PMID: 12627218
Adenoviral vector delivery of the Herpes simplex virus thymidine kinase (HSV-tk) gene in combination with the prodrug ganciclovir (GCV) has been tested in phase I clinical trials for prostate cancer...
7.
Nasu Y, Bangma C, Hull G, Yang G, Wang J, Shimura S, et al.
Prostate Cancer Prostatic Dis
. 2002 Dec;
4(1):44-55.
PMID: 12497062
We previously demonstrated significant therapeutic activities associated with adenoviral vector-mediated Herpes Simplex Virus/thymidine kinase (AdHSV-tk) with ganciclovir (GCV) in situ gene therapy in the RM-1 orthotopic mouse prostate cancer model...
8.
Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, et al.
Clin Cancer Res
. 2001 Dec;
7(12):4272-9.
PMID: 11751529
Caveolin-1, a structural component of caveolae, is overexpressed in metastatic and androgen-resistant prostate cancer and highly expressed in tumor-associated endothelial cells. The mouse cav-1 promoter was cloned and placed upstream...
9.
Thompson T, Timme T, Ebara S, Satoh T, Yang G, Wang J, et al.
Expert Opin Biol Ther
. 2001 Dec;
1(3):481-95.
PMID: 11727520
The development of effective treatments for prostate cancer is thwarted by the natural history of the disease. The biological and clinical potential of most individual cancers is uncertain. In many...
10.
Miles B, Shalev M, Aguilar-Cordova E, Timme T, Lee H, Yang G, et al.
Hum Gene Ther
. 2001 Nov;
12(16):1955-67.
PMID: 11686937
In an extended phase I/II study we evaluated 36 prostate cancer patients with local recurrence after radiotherapy who received single or repeated cycles of replication-deficient adenoviral vector (ADV)-mediated herpes simplex...